Novo Nordisk Eyes Approval For Potential First Oral GLP-1 Diabetes Pill In Young Patients

All NewsApril 23, 2026

Novo Nordisk reports phase 3 data showing oral semaglutide reduced HbA1c in adolescents with type 2 diabetes and was well tolerated.

Importance Rank:

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Novo Nordisk Eyes Approval For Potential First Oral GLP-1 Diabetes Pill In Young Patients

The UCW Newswire : Financial, Business and Tech News

Recent Headlines

Walmart is selling top-rated Swarovski hoop earrings that come in 3 colors for just $21

Heads up: US bond market closed for Veterans Day as stocks face a hot CPI hangover

Amazon’s bestselling metal storage shed with lockable doors is only $110

How Singapore became a linchpin of China’s AI chip trade

Anthropic IPO valuation calculator: How much is it really worth?